Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.

Ondrej FialaPavel OstašovAneta RozsypalováMilan HoraOndřej ŠorejsJan ŠustrBarbora BendováIvan TrávníčekJan FilipovskýJindřich FínekTomáš Büchler

Published in: Targeted oncology (2021)

The results of this retrospective study suggest that the use of BBs is associated with favorable outcomes for patients with mRCC treated with sunitinib or pazopanib in the first line.

Keyphrases

metastatic renal cell carcinoma
healthcare
adverse drug
newly diagnosed
emergency department
type diabetes
adipose tissue
weight loss
insulin resistance